Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Foxiga Korea Local Phase 4 Study
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT02564926
- Locations
- 🇰🇷
Research Site, Wonju-si, Korea, Republic of
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Kurume University
- Target Recruit Count
- 100
- Registration Number
- NCT02528019
- Locations
- 🇯🇵
Kurume University Hospital, Kurume city, Japan
DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Diabetes Frail Ltd
- Registration Number
- NCT02484209
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 939
- Registration Number
- NCT02471404
- Locations
- 🇸🇰
Research Site, Vrutky, Slovakia
Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2015-07-28
- Target Recruit Count
- 88
- Registration Number
- NCT02462369
Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Foundation for the National Institutes of Health
- Target Recruit Count
- 100
- Registration Number
- NCT02443922
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 154
- Registration Number
- NCT02426294
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 444
- Registration Number
- NCT02419612
- Locations
- 🇬🇧
Research Site, Dundee, United Kingdom
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 4
- Registration Number
- NCT02373865
- Locations
- 🇩🇪
GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden, Germany
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Kansai Electric Power Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT02312063
- Locations
- 🇯🇵
Kansai Electric Power Hospital, Osaka, Japan
🇯🇵Saiseikai Noe Hospital Osaka, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.